Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
Ameenathul Mazaya FawzyJose Miguel Rivera-CaravacaPaula UnderhillLaurent FauchierGregory Y H LipPublished in: Diabetes, obesity & metabolism (2022)
Use of SGLT2 inhibitors was associated with a significant reduction in the risk of incident heart failure and adverse cardiovascular outcomes but not ventricular arrhythmias.